• Molecular NameValproic_acid
  • SynonymDi-n-propylacetic acid; Di-n-propylessigsaure; Dipropylacetic acid; DPA; Kyselina 2-propylvalerova; Myproic Acid; n-Dipropylacetic acid; n-DPA; Propylvaleric acid; Sodium hydrogen divalproate; Valproate semisodique [French]; Valproate semisodium; Valproato semisodico [Spanish]; Valproatum seminatricum [Latin]
  • Weight144.214
  • Drugbank_IDDB00313
  • ACS_NO99-66-1
  • Show 3D model
  • LogP (experiment)2.8
  • LogP (predicted, AB/LogP v2.0)2.66
  • pka4.6
  • LogD (pH=7, predicted)0.56
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)0.32
  • LogSw (predicted, AB/LogsW2.0)3.34
  • Sw (mg/ml) (predicted, ACD/Labs)2.09
  • No.of HBond Donors1
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds5
  • TPSA37.3
  • StatusFDA approved
  • AdministrationOral, intravenous
  • PharmacologyA chemical compound that has found clinical use as an anticonvulsant and mood-stabilizing drug, primarily in the treatment of epilepsy, bipolar disorder, and less commonly major depression. It is also used to treat migraine headaches and schizophrenia.
  • Absorption_value98.0
  • Absorption (description)Rapid absorption from gastrointestinal tract.
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding93.0
  • Volume of distribution (VD)0.22 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmValproic Acid is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial beta-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine.
  • Half life14 h
  • ExcretionLess than 3% excreted unchanged in urine.
  • Urinary Excretion1.8
  • Clerance0.11 ml/min/kg
  • ToxicityOral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A